Using a new imaging method to detect primary aldosteronism

Non Invasive Imaging Methods for Detecting Primary Aldosteronism： a Clinical Positron EmissionTomography (PET) Study of 18F-Pentixather

This study is testing a new imaging method to see if it can better detect primary aldosteronism in patients, especially those with adrenal hyperplasia, who may need surgery.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 20 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: The First Affiliated Hospital of Dalian Medical University (other)
• Drugs / interventions: radiation
• Locations: 1 site (Dalian, Liaoning)
• Trial ID: NCT06581744 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the effectiveness of a novel imaging agent, 18F-Pentixather, for detecting primary aldosteronism, particularly in patients with adrenal hyperplasia. The study aims to assess the radiation dosimetry and the sensitivity and specificity of this imaging method compared to traditional techniques. By utilizing a promising chelation strategy, the trial seeks to improve the detection rates of aldosterone-producing adenomas, which are often challenging to identify. The trial will involve patients diagnosed with primary aldosteronism who are willing to undergo surgery or have had a recurrence after surgery.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with primary aldosteronism who are considering surgery or have had a recurrence of the condition.

Not a fit: Patients who are pregnant, lactating, or have severe claustrophobia or critical illnesses that prevent them from participating will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more accurate and non-invasive detection of primary aldosteronism, improving patient outcomes and treatment strategies.

How similar studies have performed: While this approach is novel, previous studies using similar imaging techniques have shown promise in detecting aldosterone-producing adenomas.

Eligibility criteria

Inclusion Criteria:

1. Patients diagnosed with primary aldosteronism and willing to undergo surgery
2. Clinically highly suspected of primary aldosteronism, but the diagnostic test cannot clearly identify the patients
3. Postoperative recurrence in patients with primary aldosteronism

Exclusion Criteria:

1. Pregnant and lactating women.
2. Patients with poor autonomous behavior ability, severe claustrophobia, and critically ill patients requiring life support who are unable to cooperate in completing the examination.
3. There are other situations where patients are not suitable for this examination

Where this trial is running

Dalian, Liaoning

• First Affiliated Hospital of Dalian Medical University — Dalian, Liaoning, China (RECRUITING)

Study contacts

• Study coordinator: Fangfang Sun, MD

Conditions: Primary Aldosteronism Due to Adrenal Hyperplasia, Primary aldosteronism, Radiation Dosimetry, 18F-Pentixather